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Abstract 
Purpose: To develop mathematical formulae to aid the selection of antibiotics most appropriate in the 
empirical treatment of infections.  
Methods: Formulae quantifying the characteristics of antibiotics with regard to their cost and activity 
against associated bacterial isolates of given infections were derived from probability laws. Data from 
records of culture sensitivity test results were compiled and analysed to ascertain bacterial pathogen 
associations with infections and their sensitivities to prescribed antibiotics. Applicability of derived 
formulae was demonstrated in the rational selection of antibiotics most appropriate in the empirical 
treatment of urinary tract infections (UTIs) in selected hospitals in Lesotho.  
Results: Escherichia. coli, followed by Klebsiella spp, Proteus spp, non-haemolytic Streptococci, 
Streptococcus pyogenes and then, Pseudomonas spp were identified as the most common 
uropathogens at the hospitals studied.  Two mathematical formulae were derived and used in 
quantifying activity and cost characteristics of prescribed antibiotics. Cefotaxime, followed by 
ciprofloxacin - were considered most appropriate for use in treating UTIs empirically among inpatients of 
the hospitals.  
Conclusion: Quantifying and using procedurally antibacterial activities and cost characteristics of 
antibiotics provides a suitable means of making antibiotic choices in the empirical treatment of 
infections. 
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Empiric antibiotic treatment of infections, though 
commonly done in medical practice, presents 
formidable challenges to prescribers [1,]. In 
developing countries where laboratory assisted 
information is least used as an aid to infection 
diagnosis and appropriate prescribing of 
antimicrobials, this may remain a major means of 
treating infections [2]. Making antibiotic choices 
for empiric treatments of infections, however, can 
be complex and difficult. It requires logical 
reasoning in which prescribers’ use of their 
knowledge of relevant therapeutic and cost 
properties of all antibiotics legible for prescribing 
becomes important [1,3]. 
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To be seen as appropriately prescribed, 
antibiotics need to be selected on comparative 
basis to enable the selection of an agent or 
agents that is/are most cost-effective in treating 
an infection in question. Considerations in such 
instances need to be given essentially to factors 
contributing to the clinical efficacy as well as the 
safety of the selected agent(s). Identification and 
hence appropriate targeting of bacterial 
pathogens most likely to be implicated in the 
infection being treated is crucially important. 
Knowledge about the antibiotic’s spectrum of 
activity, its adverse effect profiles, 
pharmacokinetic disposition and dosage likewise 
are important factors to be considered in the 
choice of therapy [4].  
 
In situations where correct lines of reasoning are 
applied, antibiotics are most likely to be selected 
and prescribed appropriately. The reverse 
logically will be true in events of inappropriate 
prescribing of the agents when flawed lines of 
reasoning are used in making such choices [5].   
Dosage regimens of antibiotics recommended in 
treatment guidelines or as individualised in 
patients with specific prevailing clinical conditions 
are designed based on the pharmacodynamic 
and pharmacokinetic properties of the agents. It 
is reasonable on this account to assume that the 
major determinant of what choice of antibiotic 
one prescribes in treating a given infection would 
be the antibacterial activities and costs of the 
agents from which such choices are made. On 
this basis and on the assumption that selected 
antibiotics would be used in their recommended 
doses, it is practically realistic to base the 
selection of antibiotics on antibacterial activity 
and cost properties of the agents. As a further 
feasible option it is also possible to quantify such 
properties as numeric values to enable 
comparisons of the agents on a linear scale as 
decisions are made on their choices.  This study 
developed and demonstrated the practical use of 
formulae in selecting antibiotics most appropriate 
in the empiric treatment of infections in clinical 
environments comprising five hospitals in the 




We derived and used formulae based on 
probabilities of pathogens’ sensitivities to 
antibiotics, their incidences of isolation from 
specimens taken from sites of infections as well 
as costs of antibiotic treatments in a procedure 
formulated for appropriate selection of antibiotics 
in the empiric treatment of infections. In the 
derivations of the formulae we considered in 
principle that:   
infections at a given anatomic body site can be 
caused by any one, some or all of the bacterial 
pathogens commonly associated with infections 
at the site; the chances of a given pathogen 
being the cause of an infection are equal to the 
pathogen’s incidence of isolation from specimens 
taken from the site of the given infection; and that 
the chances of a prescribed antibiotic terminating 
the growth and hence the process of infection of 
a given pathogen are equivalent to the chances 
of the pathogen being sensitive to the antibiotic.  
Based on the above considerations, we 
postulated that the chances of a pathogen, e.g.  
‘pathogen A’ being the causative agent of an 
infection and the chances of it being sensitive to 
a prescribed antibiotic at the same time can be 
determined as the product of two probabilities 
according to the laws of probability [6,7]; these 
are the probability of ‘A’ being isolated from the 
infection (P(iA)) and the probability of ‘A’ being 
sensitive to the prescribed antibiotic (P(sA)). By 
interpretation the product of these two 
probabilities is the probability or the chances of 
the prescribed antibiotic being active against 
pathogen A. Mathematically this can be 
expressed as P(iA) ∩ P(sA).  
 
We introduced, defined and derived 
mathematical expressions for quantifying 
relevant terms that characterised the activity and 
cost properties of antibiotics. These included 
“overall activity (OA)” and “percentage overall 
activity (POA)” of a prescribed antibiotic and also 
“antibiotic treatment success to failure ratio 
(ATSFR)” and “antibiotic selection factor (ASF)”.  
Antibiotic treatment success ratio (ATSR) and 
antibiotic treatment failure ratio (ATFR) were 
other terms we introduced and from which we 
determined ATSFR. They are the respective 
probabilities of using a given antibiotic to 
successfully or unsuccessfully treat an infection 
for which common isolates and their sensitivity 
patterns to the given antibiotic are known. These 
are directly proportional to the antibiotic’s 
percentage overall activity in the case of ATSR 
or its percentage overall resistance (POR) in the 
case of ATFR. Mathematically ATSR = C*POA 
and ATFR = C*POR. The proportionality 
constant “C” in the two formulae is presumed to 
be related to characteristics inherent to the 
antibiotic. These, like the disposition kinetics of 
the antibiotic, particularly its penetration of 
infected tissue, may equally influence the activity 
of the antibiotic against infecting pathogens. If 
determined, “C” can serve as a useful numeric 
factor in deciding whether the antibiotic can or 
cannot be used in treating certain infections.   
    
Overall activity (OA) by our definition is the 
probability of a prescribed antibiotic being active 
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against all possible causative pathogens of a 
given infection. It is equal to the sum total of the 
products of the probabilities of the individual 
pathogens being isolated from the infection and 
the probabilities of their being sensitive to a 
prescribed antibiotic. In its derivation we used a 
method similar to that used by Blondeau and 
Tillotson in a study in which they proposed the 
use of percentage overall activity as a basis for 
making rational choices of antibiotics.[9] 
Designating pathogens commonly associated 
with a given infection as A, B, C, ….N, we 
expressed the value of OA mathematically as in 
Eq 1.  
OA = P(iA)∩P(sA) + P(iB)∩P(sB) + P(iC)∩P(sC) …….+ 
P(iN)∩P(sN) ……………………………………… (1)      
 
Percentage overall activity (POA) of an antibiotic 
is an expression of OA as a percentage of the 
sum total of the incidences of isolation of 
pathogens associated with the infection, as 
shown in Eq 2. 
POA = {(OA)/( P(iA) + P(iB)+ P(iC) ……+ P(iN))}100 
…………………………………………….. (2) 
 
where P(iA)+P(iB)+P(iC) …+P(iN) is the sum total of 
the incidences of isolation of pathogens 
associated with the infection. It is a weighted 
average of pathogen sensitivities relative to their 
probabilities of isolation and is a characteristic 
property of the antibiotic that determines its 
chances of eradicating any or all of the 
pathogens which could possibly be a causative 
agent of the infection. 
  
The term ATSFR refers to the ratio of an 
antibiotic’s treatment success rate to its 
treatment failure rate. It is a numeric factor that 
characterizes the effectiveness of an antibiotic in 
terms of its chances of being successfully used 
to treat a given infection as per chance of its 
failure to treat that infection. It is calculated from 
the relationship ATSFR = ATSR/ATFR = 
POA/POR = POA/(100 – POA), where POA is 
expressed as a percentage as defined above. 
The higher the ATSFR of an antibiotic, the more 
effective it will be in treating an infection in 
question. 
 
Antibiotic selection factor (ASF) is a measure of 
the extent to which the cost of an antibiotic limits 
its selection for prescribing irrespective of its 
ATSFR. It is a preferred parameter to be used in 
the selection process when consideration is to be 
given to antibiotic costs. It is derived from Eqs. 3 
and 4, respectively, in separate instances when 
choices are to be made among oral antibiotic 
formulations on one hand and among parenteral 
formulations on the other.  
Oral formulations: ASF = ATSFR / Cost of 
antibiotic per course of treatment ……. (3) 
Parenteral formulations: ASF = ATSFR / Daily 
cost of antibiotic treatment ……….. (4) 
 
We considered that parenteral preparations often 
may not be used for the full course of antibiotic 
therapy and therefore decided to use daily cost 
of antibiotic treatment instead of cost of antibiotic 
per course of treatment in determining ASF for 
parenteral antibiotic formulations. Antibiotics with 
the highest ATSFR or ASF among a group of 
antibiotics considered for use in treating a given 
infection are selected in preference to those with 
lower ATSRF or ASF. 
 
We compiled retrospectively over a five year 
period data from records of culture sensitivity test 
results obtained from microbiology laboratories of 
five hospitals in Lesotho. This included the now 
defunct Queen Elizabeth II referral hospital and 
the Motebang, Berea, Maluti and Scott hospitals. 
Specimens tested for microbial culture were 
collected from sites of various infections among 
inpatients. Five thousand and seven (5007) data 
records were analysed to determine pathogen 
associations with various infections, their 
incidences of isolation as well as their sensitivity 
patterns to formulary antibiotics. We determined 
the ATSFR and ASF of various antibiotics in the 
exemplary case of UTI (1713 cases) and 
demonstrated how these values can be used in 
making antibiotic choices in the empiric treatment 
of this infection among inpatients of our study 




Ethical permissions were granted by the Lesotho 
Ministry of Health and Social Welfare and also 
the ethics committee of North-West University 
(ref no. 06K17) where the principal researcher 
was a PhD student, for the conduct of this 




Bacterial isolates commonly isolated from urine 
specimens which are hence considered most 
common causative agents of UTI among 
inpatients of study site hospitals were found, and 
in  order of their frequencies of isolation, to be 
Escherichia coli, Klebsiella spp, Proteus spp, 
Non-haemolytic streptococci, Streptococcus 
pyogenes and Pseudomonas spp. Frequencies 
of isolation of these pathogens, their sensitivities 
to commonly prescribed antibiotics and also the 
POAs of such commonly prescribed antibiotics 
as determined are also as shown in Table 1. 
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Table 1: Percent overall activity determinations of antibiotics against major pathogens associated with urinary 
tract Infections among inpatients (specimen: urine)  
 
ABBREVIATIONS: FI (Frequency of isolation); %FI (Percentage Frequency of isolation); P(i) (Probability of pathogen isolation); P(s) 
(Probability of pathogen sensitivity to antibiotic); %S (Pathogen sensitivity to antibiotic); OA (Overall 
activity); POA (Percentage overall activity)
Table 2: Antibiotic selection in the empiric treatment of urinary tract infections based on antibiotic activity and 
cost considerations 
 
                              Antibiotic selection determining factors          Selected antibiotics 
Antibiotics POA POR ATSFR Antibiotic 
cost per day 






Cefotaxime Inj.  93 7 13.3 17.80 0.75 1 2 
Ciprofloxacin 90 10 9 8.50 1.1 2 1 
Chloramphenicol 60 40 1.5 4.48 0.33 3 3 
Tetracycline 35 65 0.5 1.96 0.26 4 4 
 
Abreviations:   ASF (Antibiotic selection factor); ATSFR (Antibiotic treatment success to failure ratio); POA (Percentage 
overall activity); POR (Percentage overall resistance); PF (Parenteral formulation) COT (Course of treatment); OF (Oral 
formulation): Antibiotic cost in ZAR ( South African Rand). 
 
ATSFR and ASF values of the prescribed 
antibiotics as further determined from calculated 
POAs are recorded in Table 2. Based on their 
ATSFR values (Table 2), cefotaxime, followed by 
ciprofloxacin, were most appropriate in the 
empiric treatment of UTI in the patient group 
considered for this study. The POAs of ampicillin, 
co-trimoxazole, tetracycline and chloramphenicol 
(Table 1) were comparatively lower than those of 
cefotaxime and ciprofloxacin and disqualified the 
use of these antibiotics in the empiric treatment 
of UTI in the patient group. In terms of their ASF 
values (Table 2), ciprofloxacin among the oral 
antibiotic formulations was considered most 
appropriate for the empiric treatment of UTI 
among the patient group studied. 
Probabilities of pathogen sensitivities to antibiotics and 
antibiotic activities against bacterial isolates (P(i)∩P(s)) 
    Ampicillin Co-trimoxazole Tetracycline 
Pathogen FI %FI P(i) 
P(s) P(i)∩P(s) P(s) P(i)∩P(s) P(s) P(i)∩P(s) 
Non-Haem strep 40 2.4 0.024 0.71 0.017 0.32 0.008 0.51 0.01 
Streptococcus. 
pyogenes 40 2.4 0.024 0.81 0.019 0.21 0.005 0.56 0.013 
Escherichia coli 1262 75.5 0.755 0.16 0.121 0.35 0.260 0.32 0.24 
Klebsiella spp 236 14.1 0.141 0.18 0.025 0.32 0.045 0.37 0.05 
Proteus spp 71 4.2 0.042 0.28 0.012 0.24 0.010 0.19 0.03 
Pseudomonas spp 23 1.4 0.014 0.16 0.002 0.19 0.003 0.31 0.004 
OA     0.196  0.32  0.35 
POA    19.6 32.0 35.0 
 
Chloramphenicol Ciprofloxacin TGC (Cefotaxin) Pathogen FI %FI P(i) 
P(s) P(i)∩P(s) P(s) P(i)∩P(s) P(s) P(i)∩P(s) 
Non-Haem strep 40 2.4 0.024 0.74 0.01 1.00 0.02 0.91 0.02 
S. pyogenes) 40 2.4 0.024 0.42 0.01 0.80 0.02 0.75 0.02 
Escherichia coli 1262 75.5 0.755 0.57 0.43 0.78 0.59 0.88 0.66 
Klebsiella spp 236 14.1 0.141 0.53 0.07 0.74 0.10 0.49 0.07 
Proteus spp 71 4.2 0.042 0.48 0.07 0.90 0.04 0.76 0.03 
Pseudomonas spp 23 1.4 0.014 0.39 0.005 0.90 0.13 0.91 0.13 
OA     0.595  0.90  0.93 
POA    59.5 90.0 93.0 
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Mathematical steps used in developing formulae 
for use in selecting antibiotics for the empiric 
treatment of infections were as outlined in the 
methodology. Apart from a study by Blondeau 
and Tillotson in which a formula-based 
methodology antibiotic selection was proposed 
[8], our search of the literature provided no 
information on any other study in which formulae 
were developed for use in procedures of 
antibiotic selection for the empiric treatment of 
infections. In effect, no comparisons of results for 
this study were made with results of similar 
studies to authenticate this developed process of 
antibiotic selection. Cost of antibiotics as used in 
the formula was treated as a linear function.  This 
may be argued as having a negative effect of 
unduly diminishing the value of ASF, the 
quantified characteristic of the antibiotic with a 
cost component. Such arguments 
notwithstanding, costs of antibiotics can be 
considered as the same in situations where 
antibiotics from which selections are made are 
relatively cheap. In such instances, other factors 
may count most in the selection process. In 
clinical environments where cheaper traditional 
antibiotics are dominantly used, this may actually 
be the case. In such clinical environments as 
exemplified by hospitals in Lesotho, 
considerations of other factors, like POAs or 
ATSFRs as determined in this study, may 
assume prominence over costs in antibiotic 
selection processes. Costs of courses of 
antibiotic treatment most frequently used in 
Lesotho, as determined from costs of antibiotics 
at the time of data collection lied between 
ZAR1.20 – ZAR11.20 (South African rands) 
(approximately US$0.16 –  US$1.50 ).  
 
Points of note on the practical use of derived 
formulae in making antibiotic choices  
 
For the practical use of POAs or ATSFRs and 
ASFs in the rational selection of antibiotics, the 
following need to be taken into consideration as 
decisions are made in the choice of an antibiotic.   
An antibiotic with the highest ATSFR or ASF 
should be selected for prescribing in favour of 
those with lower values of the selection factors.  
An antibiotic’s ATSFR primarily determines its 
effectiveness. For this reason antibiotics may be 
compared on the basis of their ASF values in a 
second step of the selection process after they 
have been selected on the basis of their ATSFR 
values. Based solely on the ASF, it is possible for 
extremely cheap antibiotics to score relatively 
well even if they are not very effective.  
 
The final decision on which antibiotic to prescribe 
in preference to others must equally consider the 
therapeutic uses of the agents. These include, 
for example, their side-effects and toxicities and 
patients allergies to them. Further, the drugs’ 
physicochemical and pharmacokinetic properties, 
including their clearances and the extents of 
binding to proteins may also have to be taken 
into consideration. Antibiotics’ physicochemical 
properties and the extents of their binding to 
proteins may affect their ability to penetrate 
tissues and concentrate at sites of infections [2]. 
The clearance of the antibiotic determines its 
duration of action. The World Health 
Organization in this aspect emphasised that 
prescribers should select the best possible 
antibiotics that have optimal durations of actions 
to prevent the emergence of resistant strains of 
infecting pathogens [5]. Other factors like 
concomitant disease states may also have to be 
considered in the selection process. Older 
patients with hearing deficits, for example, are 
poor candidates for potentially ototoxic 
aminoglycoside therapy and so also are patients 
with a pre-existing seizure to whom imipenem 
therapy may not have to be given if a less toxic 
therapy can be used [3].  
 
On the same note, antibiotics with certain known 
characteristics that preclude their use in certain 
infections may also not be considered in the 
selection process for first choice prescribing even 
if their ASF or ATSRF values are higher than 
those of other antibiotics from which the selection 
is made. Ciprofloxacin can be cited as a classic 
example in this case. Even if the antibiotic 
demonstrates higher ATSRF and ASF values 
than other antibiotics, it may not be selected as a 
first choice antibiotic in treating lower respiration 
tract infections in which Streptococcus 
pneumoniae may be a causative agent. The 
antibiotic is noted to have moderate activity only 
against gram-positive cocci and is precluded in 
the empiric treatment of pneumococcal 
pneumonia [9]. ATSFR and ASF values by these 
notations may be taken only as guiding 
documentations on the characteristics of 
antibiotics which may help in antibiotic selection.  
 
Parenteral formulations are more expensive in 
terms of monetary costs than oral preparations 
and they would generally have lower ASFs than 
oral preparations. This is exemplified in the case 
of cefotaxime injection (Table 1). In antibiotic 
selection, both types of formulations can be 
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compared only on the basis of their ASTFRs and 
not their ASF values.   
 
Study limitations and recommendations 
 
Laboratories had the practice of testing selected 
antibiotics against certain types of bacterial 
isolates only. This was a limitation of the study 
since data for the practical demonstration of the 
use of the formulae were collected 
retrospectively. As a result, we were unable to 
calculate POA values for other commonly 
prescribed antibiotics. Antibiotics like the 
aminoglycosides (gentamicin and amikacin), 
nitrofurantoin and nalidixic acid which were also 
observed to be prescribed for urinary tract 
infections were for example tested against gram-
negative bacilli (GNB) only. They were not tested 
against gram-positive cocci isolates like non-
haemolytic streptococci, and Streptococcus 
pyogenes which were also identified as 
associated causative agents of UTI in the patient 
group studied. In effect, we could not calculate 
ASTFR and ASF values for these antibiotics to 
enable their comparisons with antibiotics from 
which the selection was made in illustrating the 
practical use of the derived formulae. 
Retrospective data collection also limited the 
ability of the study to identify and associate 
precise members of certain species of bacterial 
pathogens with infections from which they have 
been isolated. Such pathogens like Proteus and 
Klebsellia were identified just by their species 
names as recorded by laboratory staff.  
In spite of these limitations, we consider our 
derived formulae authentic. We, however, 
recommend further studies to authenticate their 
clinical effectiveness before recommending their 




Quantification of properties of antibiotics as 
measurable entities in respect to their therapeutic 
efficacies and costs has been successfully done 
in this study using formulae derived for the 
purpose. The use of these formulae was 
demonstrated and was found to be a reliable 
means of selecting antibiotics appropriately in the 
empiric treatment of infections. In given clinical 
environments where the formulae are used in 
procedures of selecting antibiotics, it is 
recommended that periodic revisions of 
calculated antibiotic selection parameters are 
carried out to ensure therapeutic effectiveness of 
selected antibiotics. For such revisions, it is 
necessary to make regular updates of lists and 
frequencies of isolation of pathogens associated 
with infections and their antibiotic sensitivities as 
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